Gemcitabine and CT-011 for Resected Pancreatic Cancer
A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer
Sponsor: Augusta University
Terminated
Drug supply issues
A PHASE2 clinical study on Cancer of the Pancreas and Neoplasms Pancreatic, this trial is terminated or withdrawn. The trial is conducted by Augusta University and has accumulated 10 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Terminated PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Feb 2017 — Oct 2017 [monthly]
Suspended PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Augusta University
For direct contact, visit the study record on ClinicalTrials.gov .